Fusion Antibodies PLC (FAB) - Total Assets
Based on the latest financial reports, Fusion Antibodies PLC (FAB) holds total assets worth GBX1.81 Million GBX (≈ $220.47 USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Fusion Antibodies PLC shareholders equity for net asset value and shareholders' equity analysis.
Fusion Antibodies PLC - Total Assets Trend (2006–2025)
This chart illustrates how Fusion Antibodies PLC's total assets have evolved over time, based on quarterly financial data.
Fusion Antibodies PLC - Asset Composition Analysis
Current Asset Composition (March 2025)
Fusion Antibodies PLC's total assets of GBX1.81 Million consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 27.1% |
| Accounts Receivable | GBX332.00K | 25.1% |
| Inventory | GBX269.00K | 20.3% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Fusion Antibodies PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Fusion Antibodies PLC (FAB) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fusion Antibodies PLC's current assets represent 95.2% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 27.1% of total assets in 2025, up from 12.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 25.1% of total assets.
Fusion Antibodies PLC Competitors by Total Assets
Key competitors of Fusion Antibodies PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $1.30 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.48 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Fusion Antibodies PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.80 | 3.25 | 6.32 |
| Quick Ratio | 1.45 | 2.73 | 5.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX620.00K | GBX991.00K | GBX4.09 Million |
Fusion Antibodies PLC - Advanced Valuation Insights
This section examines the relationship between Fusion Antibodies PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.48 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -45.3% |
| Total Assets | GBX1.32 Million |
| Market Capitalization | $193.60K USD |
Valuation Analysis
Below Book Valuation: The market values Fusion Antibodies PLC's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Fusion Antibodies PLC's assets decreased by 45.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fusion Antibodies PLC (2006–2025)
The table below shows the annual total assets of Fusion Antibodies PLC from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | GBX1.32 Million ≈ $160.97 |
-45.33% |
| 2024-03-31 | GBX2.42 Million ≈ $294.44 |
+17.36% |
| 2023-03-31 | GBX2.06 Million ≈ $250.89 |
-58.05% |
| 2022-03-31 | GBX4.92 Million ≈ $598.01 |
-15.69% |
| 2021-03-31 | GBX5.83 Million ≈ $709.34 |
-3.48% |
| 2020-03-31 | GBX6.04 Million ≈ $734.89 |
-3.25% |
| 2019-03-31 | GBX6.24 Million ≈ $759.55 |
-13.40% |
| 2018-03-31 | GBX7.21 Million ≈ $877.08 |
+234.33% |
| 2017-03-31 | GBX2.16 Million ≈ $262.34 |
+15.40% |
| 2016-03-31 | GBX1.87 Million ≈ $227.34 |
+403.68% |
| 2015-03-31 | GBX370.96K ≈ $45.14 |
+18.18% |
| 2014-03-31 | GBX313.89K ≈ $38.19 |
+3.36% |
| 2013-03-31 | GBX303.69K ≈ $36.95 |
-17.92% |
| 2012-03-31 | GBX370.00K ≈ $45.02 |
-47.52% |
| 2011-03-31 | GBX705.00K ≈ $85.78 |
-13.92% |
| 2010-03-31 | GBX819.00K ≈ $99.65 |
-0.24% |
| 2009-03-31 | GBX821.00K ≈ $99.89 |
-26.50% |
| 2008-03-31 | GBX1.12 Million ≈ $135.91 |
+5.88% |
| 2007-03-31 | GBX1.05 Million ≈ $128.36 |
+113.56% |
| 2006-03-31 | GBX494.00K ≈ $60.11 |
-- |
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more